| __timestamp | MannKind Corporation | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 2652041 |
| Thursday, January 1, 2015 | 108402000 | 2361587 |
| Friday, January 1, 2016 | 46928000 | 4472869 |
| Sunday, January 1, 2017 | 74959000 | 5030957 |
| Monday, January 1, 2018 | 79716000 | 4988941 |
| Tuesday, January 1, 2019 | 74669000 | 5196412 |
| Wednesday, January 1, 2020 | 59040000 | 6652774 |
| Friday, January 1, 2021 | 77417000 | 18418247 |
| Saturday, January 1, 2022 | 91473000 | 24827066 |
| Sunday, January 1, 2023 | 94314000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. MannKind Corporation and Opthea Limited, two prominent players, showcase contrasting strategies over the past decade. From 2014 to 2023, MannKind's SG&A expenses fluctuated, peaking in 2015 and 2023, with a notable 15% increase from 2020 to 2023. In contrast, Opthea Limited, starting with significantly lower expenses, saw a dramatic rise, especially between 2021 and 2023, where costs surged by over 125%. This divergence highlights MannKind's consistent yet high expenditure, while Opthea's rapid growth phase reflects its aggressive market expansion. Missing data for 2024 suggests ongoing strategic adjustments. As investors and analysts scrutinize these trends, the question remains: which approach will yield sustainable growth in the long run?
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Genmab A/S and Opthea Limited: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights
MannKind Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared